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Abstract: Optogenetics and photopharmacology enable the spatio-
temporal control of cell and animal behavior by light. Red light offers 
deep tissue penetration and minimal phototoxicity, but very few red 
light-sensitive optogenetic methods are currently available. Here, we 
developed a red light-induced homodimerization domain. We first 
showed that an optimized sensory domain of the cyanobacterial 
phytochrome 1 (CPH1) can be expressed robustly and without 
cytotoxicity in human cells. We then applied this domain to induce 
dimerization of two receptor tyrosine kinases, the fibroblast growth 
factor receptor 1 and the neurotrophin receptor trkB. With this new 
optogenetic method in hand, we activated the MAPK/ERK pathway 
non-invasively in mammalian tissue and developed multi-color cell 
signaling experiments. The light-controlled dimerizer and the red 
light-activated receptor tyrosine kinases will prove useful to regulate 
a variety of cellular processes with light. 
Optogenetics has revolutionized neuroscience and cell 
biology by providing optical, thus spatially and temporally 
precise, means to decode molecular and cellular networks. Light 
regulation of protein function is often achieved through 
genetically engineered intra- or intermolecular (un-)binding 
reactions.[1] For instance, in the light-activated GTPase Rac1[2], a 
C-terminal helix dissociates from its light-oxygen-voltage 
sensing (LOV) domain core to release inhibition of enzyme 
function. In light-activated gene regulation and membrane 
recruitment, LOV domains either homodimerize or 
cryptochromes heterodimerize with interacting factors in 
functionally relevant complexes.[3] In these photoreceptors, flavin 
cofactors (flavin mononucleotide or flavin adenine dinucleotide) 
endowing sensitivity to blue light (Figure 1a). However, blue light 
overlaps with wavelengths used for imaging of many 
fluorophores and exhibits limited tissue penetration. Application 
of red light can overcome these limitations but is restricted to 
reactions of cyclic (di)nucleotides or heterodimerization.[4] Here, 
we extended the arsenal of light-controlled reactions with a red 
light-sensing homodimerizer, which we repurposed from the 
cyanobacterial phytochrome 1 (CPH1) of Synechocystis and 
applied to activate membrane receptors orthogonally from 
fluorescent proteins and in mammalian tissue. 
Phytochromes form a diverse protein family in microbes 
and plants that senses light through bound linear tetrapyrroles 
(Figure 1a).[5] In particular, some phytochromes, including CPH1, 
are converted between red light-absorbing Pr states and far red 
light-absorbing Pfr states. In vitro, the sensory module of CPH1 
(CPH1S; Figure 1b), which corresponds to the C-terminally 
truncated protein, was shown to undergo light-dependent 
changes in oligomerization state.[6] Red light resulted in the 
homodimeric Pfr state and far red light in the monomeric Pr state 
(Figure 1c). We hypothesized that this domain may be 
developed into a new tool to control protein-protein interactions 
by red light in mammalian cells. Because CPH1S was not 
expressed in mammalian cells previously, we tested if its 
biogenesis is harmonious with mammalian protein production in 
human embryonic kidney 293 (HEK293) cells. We first fused a 
1539 basepair-fragment (CPH1S) from genomic DNA to the 
bright yellow fluorescent protein mVenus, which allowed for 
quantification of CPH1S expression in the context of a fusion 
protein. We observed weak fluorescence in HEK293 cells 
transfected with mVenus-CPH1S (Figure 1d), indicative of poor 
protein expression that may impede its straight-forward use. We 
reasoned that limited expression might originate from divergent 
codon usage of the cyanobacterial gene and mammalian host 
cells.[7] Indeed, a synthetic codon-optimized variant of the gene 
(CPH1S-o) showed increased expression without measurable 
cytotoxicity (Figure 1d and e). 
Homodimerization underlies the function of diverse protein 
families, such as kinases, cadherins, antibodies, motor proteins 
and transcription factors. For instance, for many receptor 
tyrosine kinases (RTKs) previously it was shown that 
homodimerization is required and can be sufficient for initiation 
of downstream signaling pathways, such as mitogen-activated 
protein kinases/extracellular signal-regulated kinase 
(MAPK/ERK) or phosphatidylinositol-3 kinase/Akt (PI3K/Akt) 
pathways.[8] To create a red light-activated RTK, we fused 
CPH1S-o to the far C-terminus of the murine fibroblast growth 
factor receptor 1 (mFGFR1) (Figure 2a). At this position, 
chemical homodimerization domains, such as an engineered 
FK506 binding protein (FKBP), or fluorescent proteins were 
previously incorporated.[9] The extracellular domain of the 
receptor was replaced by a myristoylation domain to obtain a 
receptor that is inert to its natural ligands.[9a,10] We next 
examined the ability of mFGFR1-CPH1S-o to activate the 
MAPK/ERK pathway in response to red light in HEK293 cells. 
Cells supplemented with the tetrapyrrole phycocyanobillin (PCB) 
responded to dim red light (I = 6.2 µW cm-2,   630 ± 5 nm) with 
strong pathway activation as measured using a transcriptional 
reporter (Figure 2b). Control experiments showed that (i) blue (I 
= 150 µW cm-2,   470 ± 5 nm) or green (I = 6.2 µW cm-2,   
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530 ± 5 nm) light did not result in pathway activation, (ii) red light 
had no effect after loss of kinase activity (Y271F and Y272F 
mutations) or on a fusion protein of mFGFR1 and FKBP (Figure 
2b). Notably, the results obtained on mFGFR1-FKBP indicated 
absence of receptor dimerization of mFGFR1-CPH1S-o in the 
dark. Finally, substituting a conserved arginine (R195) in the 
mFGFR1 catalytic domain with a negative charge, which 
prevents formation of an essential, asymmetric kinase domain 
dimer[11], abolished pathway activation, indicating that 
dimerization is required for receptor activation by CPH1S-o 
(Figure 2b). 
 
Figure 1. a) Chromophores of main photoreceptor classes (1: p-coumaric acid, 
2: flavins, 3: retinal, 4: tetrapyrroles). b) Domain structure of CPH1 with light 
sensory (CPH1S) and transmitter module (PAS: Per Arnt Sim, GAF: cGMP-
specific phosphodiesterase, adenylyl cyclase and FhlA, PHY: phytochrome, 
HK: histidine kinase). c) CPH1S can be interconverted between a mainly 
monomeric Pr state and mainly homodimeric Pfr state. d) Fluorescence 
intensity for HEK293 cells expressing mVenus (mV)-tagged CPH1S, CPH1S-o 
and FKBP. n.t.: non-transfected cells. e) Viability of HEK293 cells transfected 
with mV-FKBP or mV-CPH1S-o. In d) and e), mean values ± SD for three 
independent experiments each performed in triplicates are shown. 
 
We extended this design principle to a second RTK, the rat 
neurotrophin receptor trkB (rtrkB). Also in this case, red light 
resulted in pathway activation (Figure 2c) that depended on PCB 
(Figure S1). Immunoblotting demonstrated that activation of the 
MAPK/ERK and PI3K/Akt pathways returned to basal levels  30 
min after light illumination (Figure S2). Overall, incorporation of 
CPH1S-o, but not of other cyano- or proteobacterial 
phytochromes (Figure S3), into RTKs enabled activation of the 
receptors and key pathways by red light. 
Light absorbed by CPH1 and other phytochromes is red-
shifted compared to that absorbed by many fluorescent proteins 
(e.g. typical blue, green and red fluorescent proteins are excited 
at  440, 490 and 560 nm, resp.). This property has been taken 
advantage of in studies that applied phytochromes as spectrally-
separated fluorophores in multi-color imaging[12] Inspired by this 
work, we explored whether CPH1S-o can be combined with 
fluorescent proteins (e.g., mCerulean3:  Ex/Em = 433 / 475 nm, 
mCherry:  Ex/Em = 587 / 610 nm).[13] The goal of these 
experiments was optical actuation of cells (CPHS1-o), combined 
with optical detection of their signaling state (the first fluorescent 
protein) and viability (the second fluorescent protein) (Figure 2d). 
We first engineered transcriptional fluorescent reporters of the 
MAPK/ERK pathway in which mCerulean3 or mCherry were 
under control of the pathway-sensitive serum response element 
(SRE).[14] We next tested whether these proteins are indeed 
spectrally separated from red light used for CPH1S-o activation. 
As expected, we found that red light did not result in bleaching of 
these two proteins (Figure S4), and thus the reporters can 
faithfully detect pathway activation by mFGFR1-CPH1S-o 
(Figure 2e). Using the three components, we went on to 
demonstrate that light-induced cell signaling can be detected 
separately from cell viability in the same experiment. We 
prepared a viability reporter in which mCerulean3 was under the 
control of the constitutively active cytomegalovirus (CMV) 
promoter, and then applied this viability reporter in combination 
with the mCherry MAPK/ERK pathway reporter. We incubated 
cells either in a high concentration of DMSO to induce cell death 
or in the specific MAPK/ERK pathway inhibitor Trametinib (TRA) 
(Figure 2d). The addition of TRA reduced the red light-induced 
mCherry signal but not the mCerulean3 signal (Figure 2f). In 
contrast the addition of DMSO lead to the reduction of both 
signals (Figure 2f). Thus, taking advantage of spectral 
separation of CPH1S-o, we showed that effects of specific 
inhibitors can be distinguished from those of unspecific toxins in 
a single all-optical experiment. In future experiments, different 
colors of light may be used to independently activate two or 
more processes in the same cell or two or more cell types in a 
heterogeneous population to study cross-talk of cellular 
signaling pathways or cell-cell interactions. 
An important trait of red light is its ability to penetrate 
tissue more deeply than blue and green light. Because 
experiments with blue light in mouse models often rely on 
implants or powerful light sources[3b, 15], we tested if CPH1S-o 
can be activated directly and transdermally in tissues. Indeed, 
when illuminating HEK293 cells transfected with rtrkB-CPH1S-o 
through synthetic muscle, skin and skull (Figure S5), we found 
potent activation of signaling (Figure S6). Notably, the applied 
light intensities were easily attained with light emitting diodes 
and even lower than those used in photodynamic therapy.[16] For 
mouse abdomen (including skin, muscle, fat and spine; 
thickness 10 mm) (Figure S7), we found that the MAPK/ERK 
pathway was activated by red light in INS-1E cells transfected 
with mFGFR1-CPH1S-o (I = 3.0 mW cm-2,   647 ± 35 nm) 
(Figure S8). We chose INS-1E cells, an insulinoma model for 
pancreatic β-cells[17], for these experiments because β-cells 





 10 mm from the mouse skin. Collectively, these data show 
activation of cell signaling through mammalian tissues opening 
avenues to further non-invasive in vivo optogenetic studies. 
 
Figure 2. a) CPH1S-o (red) was incorporated in mFGFR1 or rtrkB to engineer 
red light-activated receptors. b and c) MAPK/ERK pathway activation by 
mFGFR1-CPH1S-o (b) and rtrkB-CPH1S-o (c) in response to red (R), green 
(G) and blue (B) light. Pathway activation is expressed as reporter gene levels 
in HEK293 cells. d) Multi-color experiments to test receptor/pathway inhibition 
and cell viability. (I) CMV-mCerulean3 is expressed constitutively whereas 
SRE-mCherry depends on MAPK/ERK pathway activation (mCer3: 
mCerulean3). (II) Addition of DMSO leads to cell death, resulting in neither 
mCherry nor mCerulean3 expression. (III) Addition of 0.1 µM Trametinib (TRA) 
prevents MAPK/ERK pathway activation whereas viability is not affected. 
e) MAPK/ERK pathway activation by mFGFR1-CPH1S-o in response to red 
light measured with SRE-mCherry/-mCerulean3. FBS/PMA was used as 
positive control. Activation is expressed as mCherry or mCerulean3 levels. 
f) Experimental realization of d), MAPK/ERK pathway activation in response to 
red light after treatment with DMSO or TRA. Pathway activation and cell 
viability is expressed as mCherry and mCerulean3 levels, resp. In b) and c), 
mean values ± SEM for two to 17 independent experiments each performed in 
triplicates are shown. In e) and f), mean values ± SEM for three independent 
experiments each performed in triplicates are shown. 
Light-sensitive proteins that undergo reversible inter- or 
intramolecular binding reactions are the motors of many 
optogenetic methods. By identifying and adapting the sensory 
domain of the cyanobacterial phytochrome CPH1, we introduced 
an approach for the stoichiometric, red light-induced 
homodimerization of proteins. Light-induced dimer assembly 
may be applied to regulate cell adhesion, gene transcription, or 
the cytoskeleton, potentially also by forming larger complexes 
after incorporation of multiple photoreceptor domains. 
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Phyotochrome sensory domains 
Gene fragments coding for the sensory domain of two phytochromes, CPH1 from Synechocystis 
PCC6803 and the phytochrome of Cyanothece sp. ATCC51142 (C.s.), were amplified from 
genomic DNA libraries using polymerase chain reaction (PCR) (oligonucleotides 1-4, Table S1). 
The sensory domain of the phytochrome of Nostoc sp. PCC7102 (N.s.) was amplified from 
cyanobacteria, which were lysed by boiling, using PCR (oligonucleotides 5 and 6, Table S1). In 
addition, gene fragments for the sensory domain of CPH1 and the phytochrome of 
Agrobacterium tumefaciens (A.t.) were synthesized with mammalian codon optimization 
according to the supplier’s recommendation (Epoch Life Science, Inc.) and amplified using PCR 
(oligonucleotides 7-10, Table S1). Genes are given in Table S2 and S3. 
Receptor tyrosine kinase fusion proteins 
Phytochrome sensory domains were inserted into a mFGFR1 construct that was described 
previously[1] using PCR and the AgeI and XmaI restriction enzymes (see above for 
oligonucleotides). This construct contains the complete intracellular domain of mFGFR1, a 
myriostylation membrane anchor and a HA-epitope. rtrkB-CPH1S-o was generated using 
inverse PCR (oligonucleotides 11 and 12, Table S1). Starting from mFGFR1-CPH1S-o, 
amplification produced linear double-stranded DNA products with terminal SgrAI restriction sites 
that replace the mFGFR1 catalytic domain. Products were digested with SgrAI, ligated and 
propagated in E. coli cells. The rtrkB catalytic domain was then inserted using PCR and the 
BspEI and AgeI restriction enzymes (oligonucleotides 13 and 14, Table S1). Point substitutions 
in mFGFR1-CPH1S-o (Y271F, Y272F and R195E; numbered relative to start methionine of red 
light-activated mFGFR1) were introduced using site-directed mutagenesis (oligonucleotides 15-
18, Table S1). For multi-color fluorescent reporter experiments, the CMV promoter in the 
mFGFR1-CPH1S-o expression vector was truncated for lower expression[2] using inverse PCR 
followed by blunt end ligation (oligonucleotides 19 and 20, Table S1). All constructs were 
verified by DNA sequencing and sequences are given in Table S4. 
Fluorescent transcriptional reporters 
Fluorescence transcriptional reporters (Table S5) were generated by first removing the 
luciferase gene from the pGL4.33 vector (Promega) using inverse PCR and the AscI restriction 
enzyme (oligonucleotides 21 and 22, Table S1). Genes coding for mCerulean3 or mCherry, kind 
gifts of R.Y. Tsien and M. Davidson, were inserted using PCR (oligonucleotides 23-26, Table 
S1). 
Cell culture 
HEK293 cells were maintained in DMEM and INS-1E cells[3], a kind gift of P. Maechler, were 
maintained in RPMI-1640 in a humidified incubator with 5 % CO2 atmosphere (37 °C). DMEM 
was supplemented with 10 % FBS, 100 U/ml penicillin and 0.1 mg/ml streptomycin, and RPMI-
1640 was additionally supplemented with 10 mM HEPES, 1 mM pyruvate, 2 mM L-Glutamine 
and 50 µM β-mercaptoethanol. HEK293 cells were transfected using polyethylenimine 
(Polysciences) and INS-1E cells were transfected using Lipofectamine 2000 (Invitrogen/Life 
Technologies) (see below). 
Sensory domain expression and cell viability 
An expression plasmid based on pcDNA3.1(-) was used in which a BspEI restriction site was 
placed after the fluorescent protein mVenus[4] and a glycine- and serine-rich linker.[1] CPH1S, 
CPH1S-o and FKBP domains were inserted into this plasmid using PCR (see above for 
oligonucleotides and restriction enzymes). 5 x 104 HEK293 cells in each well of 96-well clear 
bottom plates coated with poly-L-ornithine (Sigma) were transfected with 5-10 ng expression 
plasmid. Expression was assessed by measuring mVenus fluorescence in a microplate reader 
(BioTek Synergy H1) 30 h after transfection. For viability measurements after fluorescence 
measurement cells were incubated for 2 h with thiazolyl blue tetrazolium bromide (Sigma) (0.5 
mg/ml) followed by lysis with 70 µl acidic isopropanol (0.1 N HCl). Absorbance measurements 
were taken at 570 nm with 620 nm reference in the plate reader. 
MAPK/ERK pathway activation (luminescence) 
Activation of the MAPK/ERK pathway was assayed with the PathDetect Elk1 trans-Reporting 
System (Agilent). 5 x 104 HEK293 cells in each well of 96-well clear bottom plates were 
transfected with 210.3 ng total plasmid (receptor, trans-activator and trans-reporter at a ratio of 
1:30:600). 6 h after transfection, medium was replaced with CO2-independent reduced serum 
starve medium (Gibco/Life Technologies; supplemented with 0.5 % FBS, 2 mM L-Glutamine, 
100 U/ml penicillin and 0.1 mg/ml streptomycin), and 10 µM phycocyanobilin (PCB; Livchem 
Logistics) was added to the cells in the dark. After overnight incubation (37 °C, 5 % CO2), cells 
were either stimulated with light for 8 h or protected from light at 37 °C (see main text for 
wavelengths and intensities). Light intensities in an incubator equipped with 300 light emitting 
diodes was controlled with a dimmer and measured with a power meter (PM120VA, Thorlabs). 
Intensities at maximal output were 230 (red light,   630 ± 5 nm), 210 (green light,   530 ± 5 
nm) and 555 (blue light,   470 ± 5 nm) µW cm-2. Activation of receptors containing CPH1S-o 
fusion was observed for light intensities lower than 60 µW cm-2. After incubation, plates were 
washed once with PBS and processed with Luciferase One-Glo Assay System (Promega) 
following the manufacturer’s instructions. Luminescence was detected with the microplate 
reader. 
MAPK/ERK pathway activation (multi-color fluorescence) 
5 x 104 cells in each well of 96-well clear bottom plates were transfected with 251 ng total 
plasmid (viability reporter, signaling reporter and receptor at a ratio of 1:100:150). 16 h after 
transfection, medium was replaced with CO2-independent reduced serum starve medium and 
incubated in the dark (37 °C, 5 % CO2). After 5 h, 10 µM PCB and, where required, 0.1 µM 
Trametinib (GSK1120212) or 10 % DMSO were added to each well and cells were incubated for 
further 4 h in the dark. Cells were then stimulated either with red light (I = 6.2 W cm-2,   630 
 5 nm), treated with FBS (10 %) and PMA (10 ng/ml) or kept in the dark for 18 h. After 
incubation, medium was replaced by PBS and fluorescence was measured with the microplate 
reader (mCerulean3:  Ex/Em = 433 / 475 nm, mCherry:  Ex/Em = 588 / 630 nm). 
Immunoblotting (HEK293 cells) 
1 x 106 HEK293 cells in a 35 mm dish were transfected with 4.02 µg total plasmid per dish 
(receptor and empty vector and receptor at a ratio of 1:200). 6 h after transfection, medium was 
replaced with 1.5 ml reduced serum starve medium supplemented with 10 µM PCB. After 20 h, 
cells were illuminated for 3 min with red light (I = 6.2 W cm-2,   630  5 nm). Cells were then 
either immediately, or after additional 5, 15 or 30 min in the dark, washed with ice-cold PBS and 
lysed on ice in 250 µl lysis buffer per dish. Control cells, control cells without PCB treatment and 
mock transfected (m.t) cells were not illuminated and washed and lysed immediately. Lysates 
were shaken for 30 min at 4 °C and centrifuged for 20 min at 12000 rpm at 4 °C. 20 μl lysate per 
lane were separated by SDS-PAGE and electro-blotted onto PVDF membranes. Blots were 
incubated with primary antibodies (pERK1/2 #9101, dilution 1:1000; ERK1/2 #9102, dilution 
1:1000; Akt #9272, dilution 1:1000; pAkt #4060, dilution 1:2000; Cell Signaling Technology; 
ERK2 sc-153, dilution 1:1000; Santa Cruz Biotechnology) in blocking solution (5 % BSA in 
TBST) overnight at 4 °C. Secondary antibody (Goat anti-rabbit IgG(H+L)-HRP conjugated, 
Biorad) was applied at a dilution of 1:10000 for 2 h at RT. 
 
Synthetic tissues and MAPK/ERK pathway activation 
Synthetic tissues whose spectral properties match those of human skin, skull and muscle[5] were 
prepared by supplementing high purity 2 % agarose gels (Carl Roth) with dyes (Sigma) 
depending on tissue type (Figure S5). Synthetic skin was generated by supplementing 104.5 ml 
gel with 50 µg tartrazine and 3 µg amaranth. Synthetic muscle was generated by supplementing 
with 15 µg tartrazine and 15 µg amaranth. Synthetic skull was generated by supplementing 31.4 
ml gel with 75 µg tartrazine, 55 µg allura red AC, 10 µg amaranth, 25 µg prussian blue and 50 
µg brilliant blue. 10 mm of synthetic tissue correspond to 10 mm of animal tissue, except for skin 
which has 20-fold higher absorption (in this case, 10 mm of synthetic tissue correspond to 0.5 
mm of mammalian skin). HEK293 cells transiently transfected with rtrkB-CPH1S-o were 
illuminated through the synthetic tissues and further processed for luminescence measurements 
as described above. 
 
Determination of tissue penetration through animal tissue 
For measuring light penetration through head, the lower jaw and the palate bone of three 
shaved mouse heads were removed to create an opening (light that penetrated through the 
shaved scalp, the skull and the whole brain was measured). For mouse abdomen, shaved 
mouse torso was opened (light that penetrated through shaved skin, fat, muscle, spine and 
organs was measured). For illumination, a bright lamp (DG4, Sutter instruments) and a dish 
covered with black tape with a window was placed above a sensor connected to a power meter 
(Figure S7b). Three measurements were acquired each first without sample (to determine the 
initial light intensity, I0, in µW cm-2) and then with the sample (to determine transmission, T, in 
µW cm-2). All measurements were made in triplicates and penetration was calculated as T / I0. 
 
Activation of INS-1E cells through animal tissue 
Because the synthetic tissues were optimized to mimic absorption but not scattering properties, 
we also performed experiments with mouse tissues. 1.5 x 106 INS-1E cells were seeded in a 35 
mm dish and transfected with 2.5 µg total DNA per dish (receptor and empty vector at a ratio of 
1:50). 9.5 h after transfection, medium was replaced with 1.5 ml reduced serum starve medium 
supplemented 10 µM PCB and incubated for 18 h in the dark. Mouse abdomen including 
shaved skin, fat, muscle, and spine was placed in a 35 mm cell culture dish. The dish was 
covered with black tape, except for a window at its bottom and top. Cells were illuminated for 15 
min with red light (I = 3.0 mW cm-2,   647 ± 35 nm) through the mouse abdomen. Cells were 
then immediately washed, lysed, and processed as described above (dark and mock 
transfection (m.t) controls were also treated as described above). 30 μl lysate per lane were 
separated by SDS-PAGE and electro-blotted onto PVDF membranes. Blots were incubated with 
primary antibody (pERK1/2 #9101, dilution 1:1000, Cell Signaling) in blocking solution overnight 






Figure S1: MAPK/ERK pathway activation in HEK293 cells transfected with rtrkB-CPH1S-o in 
response to red light (R) stimulation (I = 6.2 µW cm-2,   630  5 nm) in the absence of added 
PCB. Pathway activation is expressed as reporter gene levels. Mean values ± SEM for one 





Figure S2: Phosphorylation of ERK1/2 (pERK1/2) and Akt (pAkt) in HEK293 cells transfected 
with rtrkB-CPH1S-o in response to red light stimulation (I = 6.2 µW cm-2,   630  5 nm, 3 min) 




Figure S3: MAPK/ERK pathway activation in HEK293 cells transfected with chimeric proteins of 
mFGFR1 and different photoreceptors from different species in response to red light (I = 6.2 µW 
cm-2,   630  5 nm). PR: Photoreceptor, C.s.: Cyanothece sp. ATCC 51142, N.s.: Nostoc sp. 
PCC 7120 and A.t.-o: A. tumefaciens. Pathway activation is expressed as reporter gene levels. 




Figure S4: Fluorescence intensity measurement of CMV-mCherry and CMV-mCerulean3 after 
18 h of red light illumination (I = 6.2 W cm-2,   630  5 nm). Mean values ± SEM for three to 




Figure S5: a) HEK293 cells transfected with rtrkB-CPH1S-o were illuminated with red light from 
the bottom through synthetic tissues in a 96-well clear bottom plate (the sides of the plates were 
covered with black tape). b-d) Absorption properties of mammalian 10 mm muscle b), 0.5 mm 
skin c) and 10 mm skull d) (circles; data taken from literature)[5] and of the corresponding 
synthetic tissues produced by spiking agarose matrices with synthetic organic dyes (squares, 




Figure S6: Activation of MAPK/ERK pathway in HEK293 cells transfected with rtrkB-CPH1S-o 
illuminated (I = 6.2 - 17.5 µW cm-2,   630  5 nm) through synthetic tissues mimicking 10 mm 
muscle, 0.5 mm skin or 3 mm skull. Mean values ± SEM for one to three independent 
experiments performed in triplicates are shown.  
  
 
Figure S7: a) and b) Set-up for measuring light penetration through the head and abdomen of a 
mouse. Red light was aimed above the shaved mouse head (thickness  7 mm) or above the 
opened mouse abdomen (thickness  10 mm). An optical sensor (diameter = 10 mm) connected 
to a power meter was placed directly under the ventral part of the brain or under the shaved 
abdomen of the mouse. c) Transmission of red light through head (circles; three samples 





Figure S8: a) INS-1E cells transfected with mFGFR1-CPH1S-o were stimulated through mouse 
tissue (thickness  10 mm) with red light (I = 3.0 mW cm-2,   647 ± 35 nm). The lamp was 
located directly below the mouse tissue to ensure all light passing through the tissue. b) 




Table S1. Oligonucleotides utilized in gene construction. Restriction sites are underlined 
Name Sequence 
1: CPH1S_XmaI_F GCTACCCGGGGCCACCACCGTACAACTCAG  
2: CPH1S_XmaI_R GCTACCCGGGTTCTTCTGCCTGGCGCAAAATG 
3: C.s._XmaI_F GATGCCCGGGATTAGTAATGTTAAAACCAGTCAAGAC 
4: C.s._XmaI_R GATGCCCGGGTTCGTCGGCTTGTCGGAGAATAATG 
5: N.s._AgeI_F GATGACCGGTAGAATAGACGTAGAATCACAAAATATTAATG 
6: N.s._XmaI_R GATGCCCGGGTTCATCGGCTTGGCGTAGAACG 
7: CPH1S-o_XmaI_F GATCCCCGGGGCAACTACTGTTCAACTGTCTGATCAATCTCTG 
8: CPH1S-o_XmaI_R GATCCCCGGGTTCTTCAGCTTGGCGCAGAATCAGGTT 
9: A.t._AgeI_F GATCACCGGTCAGCGTGAACGTCTGGAGAAAGTCATGT 
10: A.t._AgeI_R GATCACCGGTTTCTTCAGTTTTGCGCAGGACGATGC 
11: mF_inverse_SgrAI_F GATCCACCGGTGGAGCAACTACTGTTCAACTGTCTG 
12: mF_ inverse_SgrAI_R GATCCACCGGTGACGTCGAGGCGCTG 
13: rtrkB_BspEI_F GATCTCCGGAAAGTTTGGCATGAAAG 
14: rtrkB_AgeI_R CAGAAACCGGTGCCTAGGATGTCCAG 
15: mF_YY271/2FF_F GAGACATTCATCATATCGACTTCTTCAAGAAAACCACCAACGGCC 
16: mF_YY271/2FF_R GGCCGTTGGTGGTTTTCTTGAAGAAGTCGATATGATGAATGTCTC 
17: mF_R195E_F TACAGGCCCGGGAGCCTCCTGGGCTGGAGTACTGCTATAA 
18: mF_R195E_R TTATAGCAGTACTCCAGCCCAGGAGGCTCCCGGGCCTGTA 
19: truncated CMV_pcDNA3.1(-)_F TGGGAGGTCTATATAAGCAGAGC 
20: truncated CMV_pcDNA3.1(-)_R GGCGGGCCATTTACCGTAAG 
21: pGL4_inverse_AscI_F GATCATGGCGCGCCCTAAGGCCGCGACTCTAGAGTC 
22: pGL4_inverse_ AscI_R  ATGATCGGCGCGCCGGTGGCTTTACCAACAGTAC 
23: mCerulean3_AscI_F CATCAGGCGCGCCATGGTGAGCAAGGGGCGAGGAG  
24: mCerulean3_AscI_R GATCAGGCGCGCCCTAGGACTTGTACAGCTCGTCCATG  
25: mCherry_AscI_F CATCAGGCGCGCCATGGTGAGCAAGGGCGAGGAGG 
26: mCherry_AscI_R GATCAGGCGCGCCTTACTTGTACAGCTCGTCCATGCC 
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